Company Encyclopedia
View More
name
Novartis AG
NOT.DE
News
View More

Legal & General Group Plc Purchases 14,073 Shares of Novartis AG $NVS

Legal & General Group Plc increased its stake in Novartis AG by 27.5% in Q2, purchasing an additional 14,073 shares, now holding 65,156 shares valued at $7,884,000. Other institutional investors also adjusted their positions in Novartis. The company's stock opened at $132.32, with a market cap of $279.51 billion. Analysts have mixed ratings on Novartis, with a consensus rating of 'Hold' and a price target of $122.33.

Market Beat·
DE
NOT
0.00%
US
NVS
+0.37%
Market Beat·
DE
NOT
0.00%
US
NVS
+0.37%

Novartis AG $NVS Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC increased its position in Novartis AG by 5.3% in Q2, owning 7,121,414 shares worth $861.76 million. Other institutional investors also increased their positions. Novartis has a market cap of $275.09 billion and a P/E ratio of 17.79. Analysts have mixed ratings on the stock, with an average target price of $122.33. Novartis reported Q3 earnings of $2.25 per share, slightly missing estimates, with revenue up 8.5% year-over-year.

Market Beat·
US
NVS
+0.37%
DE
NOT
0.00%
Market Beat·
US
NVS
+0.37%
DE
NOT
0.00%

Verity & Verity LLC Purchases New Holdings in Novartis AG $NVS

Verity & Verity LLC acquired 3,778 shares of Novartis AG, valued at approximately $457,000, during the 2nd quarter. Other institutional investors also adjusted their positions in Novartis. The company's stock opened at $129.67, with a market cap of $273.92 billion. Analysts have mixed ratings on Novartis, with a consensus rating of 'Hold' and an average price target of $122.33. Novartis focuses on healthcare products, including prescription medicines in various therapeutic areas.

Market Beat·
US
NVS
+0.37%
DE
NOT
0.00%
Market Beat·
US
NVS
+0.37%
DE
NOT
0.00%

FDA Approves Novartis Gene Therapy Itvisma for Spinal Muscular Atrophy

Novartis AG has received FDA approval for Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA) in patients aged two and older. Itvisma is the first gene therapy targeting the genetic root cause of SMA, potentially reducing the need for chronic treatment. The approval follows positive Phase III clinical trials showing improved motor function. This marks a significant advancement in SMA treatment.

Reuters·
DE
NOT
0.00%
US
NVS
+0.37%
Reuters·
DE
NOT
0.00%
US
NVS
+0.37%

Market Chatter: Novartis to Eliminate Up to 550 Roles at Stein Facility in Switzerland

Novartis AG plans to cut up to 550 full-time jobs at its Stein facility in Switzerland by the end of 2027, according to Reuters. The company has not yet commented on the matter. This information, derived from market professionals, may include rumor and speculation, and its accuracy is not guaranteed.

fidelity·
DE
NOT
0.00%
US
NVS
+0.37%
fidelity·
DE
NOT
0.00%
US
NVS
+0.37%
© 2025 Longbridge｜Disclaimer